New Version Extends Data Cleaning and Query Functions
Phase Forward (Waltham, MA) announces significant updates to its Web Submission Data Manager, WebSDM 2.6. WebSDM 2.6 integrates with the company's InForm Integrated Trial Management EDC product Version 4.6 and other database applications, and allows InForm 4.6 users to examine source records directly in the original context to understand data cleaning status and raise queries when needed at an earlier stage. This allows for detection of anomalies and trends for safety analysis.
WebSDM 2.6 also checks data for CDISC SDTM conformance, provides Web services API for automated data loading and improved integration with external data repositories such as Janus, and is validated for use on 64-bit platforms and Oracle Database 10g.
Phase Forward, (888) 703-1122, www.phaseforward.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.